RxDoctor Payments Data
★ My doctorsLook up a doctor →

Don Smith

Psychiatry · Waterford, MINPI 1528155850

Payments from drug & device makers

$4,501in general payments, 2019–2025

Across 264 payments — averaging $17.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$860
  • AbbVie$585
  • Lundbeck LLC$474
  • Neurocrine Biosciences, Inc.$452
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$434
  • Tris Pharma Inc$319
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$4,47199%
  • Education$301%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Otsuka America Pharmaceutical, Inc.41$860
AbbVie(2 entities)34$585
Lundbeck LLC28$474
Neurocrine Biosciences, Inc.22$452
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)20$434
Tris Pharma Inc24$319
Takeda Pharmaceuticals U.S.A., Inc.25$287
Supernus Pharmaceuticals, Inc.17$165
Axsome Therapeutics, Inc.7$140
Corium, LLC9$138
Alkermes, Inc.8$125
Teva Pharmaceuticals USA, Inc.6$100
Shire North American Group Inc5$92
Vanda Pharmaceuticals Inc.5$87
Ironshore Pharmaceuticals Inc.2$45
Johnson & Johnson2$39
E.r. Squibb & Sons, L.L.C.2$38
Noven Therapeutics, LLC2$36
Sunovion Pharmaceuticals Inc.2$28
Sage Therapeutics, LLC1$26
OWP Pharmaceuticals, Inc.1$19
Collegium Pharmaceutical, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,501 in reported general payments places this provider in the 90th percentile of 1,166 psychiatry providers in Michigan.

See all psychiatry providers in Michigan →

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole19$26,982
Alprazolam88$1,071
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine26$772
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine13$730
Quetiapine Fumarate ErQuetiapine Fumarate11$543
Duloxetine Hcl24$406
Eszopiclone15$269
Bupropion XlBupropion Hcl18$218
Clonazepam23$170
Gabapentin19$140
Trazodone Hcl11$100
Escitalopram Oxalate18$98
Zolpidem Tartrate20$95
Buspirone Hcl13$78
Citalopram HbrCitalopram Hydrobromide20$49

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$860$26,98219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,166 psychiatry providers in Michigan.

Other psychiatry in Waterford

See the full list for Michigan →

Where these figures come from

Is this you, or does something look wrong? →